Compare AVNT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | ICUI |
|---|---|---|
| Founded | 1927 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2000 | 1995 |
| Metric | AVNT | ICUI |
|---|---|---|
| Price | $40.97 | $163.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $41.50 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 593.8K | 182.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | 1.31 | ★ 1.96 |
| Revenue | ★ $3,835,500,000.00 | $2,231,262,000.00 |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | $3.48 | $4.46 |
| P/E Ratio | ★ $31.48 | $82.13 |
| Revenue Growth | ★ 1.71 | N/A |
| 52 Week Low | $27.48 | $112.50 |
| 52 Week High | $46.64 | $192.85 |
| Indicator | AVNT | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.